Mounting evidence suggests that multiple sclerosis (MS) may be triggered by one of the world’s most common viruses, according to new research examining the link between Epstein-Barr virus and the autoimmune disease. Scientists have uncovered a potential mechanism explaining how the virus, which infects approximately 95% of adults worldwide, could contribute to the development of multiple sclerosis through an overactive immune response in the central nervous system.
A recent study led by researchers from the University of California, San Francisco, published in Nature Immunology, revealed that MS patients harbor an abundance of killer T cells specifically targeting Epstein-Barr virus. The research analyzed blood and cerebrospinal fluid samples from 13 multiple sclerosis patients compared to five unaffected individuals, finding virus-recognizing immune cells at levels up to 100 times higher in spinal fluid than in blood.
Understanding the Epstein-Barr Virus Connection to Multiple Sclerosis
Epstein-Barr virus, commonly known for causing “kissing disease” or glandular fever, belongs to the herpes virus family and remains dormant in the body for years after initial infection. The virus can hide inside brain cells, and nearly all people with multiple sclerosis carry this pathogen, prompting scientists to investigate a possible connection for decades.
According to neurologist Joe Sabatino from UCSF, examining these previously unstudied T cells “connects many scattered dots and gives us a new window to understand how Epstein-Barr virus contributes to this disease.” The findings build upon a landmark 2022 study involving more than 10 million people, which revealed that the risk of developing multiple sclerosis increases 32-fold following Epstein-Barr virus infection.
Immune Cell Activity in MS Patients
Research from 2024 demonstrated that T cells recognizing the virus multiplied dramatically in the blood of multiple sclerosis patients, comprising 13% of all T cells compared to just 4% for influenza-recognizing cells. In cerebrospinal fluid, this proportion reached 47%, indicating a concentrated immune response within the central nervous system.
The new study provided more detailed analysis of this immune system response. Researchers discovered that killer T cells targeting viral proteins were significantly more abundant in cerebrospinal fluid, suggesting the immune system responds to changes when the virus “awakens” from dormancy in the central nervous system.
Viral Activity and Autoimmune Response
Most multiple sclerosis patients in the study showed signs of active Epstein-Barr virus in their cerebrospinal fluid, with active viral genes appearing only in those diagnosed with the disease. This substantial difference points to an excessive immune reaction that may damage the protective myelin sheath around nerve fibers, the hallmark of multiple sclerosis pathology.
The research adds weight to the hypothesis that viral reactivation within the nervous system triggers inflammation and autoimmune attacks. However, scientists emphasize that not everyone infected with Epstein-Barr virus develops multiple sclerosis, suggesting additional genetic or environmental factors play crucial roles in disease development.
Implications for Treatment Development
These findings open new avenues for potential therapeutic interventions targeting the virus itself rather than just managing MS symptoms. Additionally, understanding this mechanism could benefit patients with other conditions potentially linked to Epstein-Barr virus, including certain cancers and autoimmune disorders.
According to Sabatino, the hope is that interventions against Epstein-Barr virus could significantly impact not only multiple sclerosis but other disorders as well, potentially improving quality of life for many patients. Meanwhile, researchers continue investigating why some infected individuals develop autoimmune conditions while others remain unaffected throughout their lives.
Further studies are expected to explore potential antiviral therapies and vaccines targeting Epstein-Barr virus as preventive measures against multiple sclerosis. However, researchers have not yet announced specific timelines for clinical trials testing these approaches in MS patients.
